Oct 26, 2020 · Scorpion is a pioneering clinical-stage oncology company redefining the frontier of precision medicine to deliver transformational therapies for larger populations of patients with …

A lot of companies try to advertise cross-collaboration. At Scorpion, it’s not only true, but better than I could have imagined.

Scorpion Therapeutics Announces $150 Million Series C Financing to Advance Leading Clinical-stage Precision Oncology Pipeline

At Scorpion Therapeutics, we are expanding the reach of precision medicine to more people with untreatable or treatment-resistant cancer.

Driven by advances in cancer biology, medicinal chemistry and data sciences over the last two decades, the field of cancer therapy has entered a new era of more targeted, genetic-based …

Oct 13, 2023 · Scorpion Therapeutics Accelerates Precision Oncology 2.0 for More Patient Populations. Read More

– January 13, 2022 – Scorpion Therapeutics, Inc. (“Scorpion”), a next-generation oncology company pioneering Precision Oncology 2.0, today announced a collaboration with …

BOSTON, MA. – January 7, 2021 – Scorpion Therapeutics, Inc., a next-generation precision oncology company, today announced the closing of an oversubscribed Series B financing, …

Address. 2 Tower Place 3rd Floor South San Francisco, Phone. 781-288-5760 . Contact us

Scorpion’s Phase 1/2 clinical trial is a multi-center, global, open-label study designed to evaluate the safety and tolerability of STX-478 in multiple ascending doses for patients with locally …